Plain-English translation of NCT06224023 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are investigating whether presepsin — a substance that your body produces in response to infection — can be measured in abdominal fluid to predict how well patients with chronic liver failure will do. This marker has shown promise in blood tests for detecting infections and predicting survival in liver disease, but this study will examine whether measuring it in the fluid that accumulates in the abdomen provides even better insight into patient outcomes.
Doctors need better tools to predict which patients with advanced liver disease are at highest risk of serious complications or death. This medication may help identify those patients earlier, allowing for better medical planning and care.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have a standard procedure called paracentesis, where a doctor uses a needle to safely collect a small sample of fluid from your abdomen. This fluid will then be tested to measure presepsin levels. The study involves one main visit for this procedure; researchers will use your sample and medical information to help determine whether this marker can predict outcomes in liver disease.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Romania
Enrollment target
~30 participants
Started
August 2024
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mihai Ciocirlan
Carol Davila University of Medicine and Pharmacy
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.